A Phase 3 trial of OMS721 in IgA nephropathy.
Phase of Trial: Phase III
Latest Information Update: 15 Aug 2017
At a glance
- Drugs OMS 721 (Primary)
- Indications IgA nephropathy
- Focus Therapeutic Use
- 15 Aug 2017 According to Omeros Corporation media release, company is working with US FDA to finalize the protocol for this trial and expect to initiate the enrollment by end of the year 2017.
- 16 Nov 2016 New trial record
- 31 Oct 2016 According to an Omeros Corporation media release, company plans to initiate this trial in 2017 if fast track designation is granted by FDA.